NATALEE trial has reached primary end point (iDFS) in interim analysis, supporting the potential role of ribociclib to improve outcomes for patients with stage II or III, HR+/HER2- early breast cancer at high risk of recurrence. Further follow up needed to confirm the benefit
The SONIA trial challenges current CDK4/6 inhibition sequencing strategies for patients with HR+/HER2- advanced breast cancer. Results suggest the use of CDK4/6i in first line treatment does not improve PFS2, OS or QoL but does increase toxicities, costs and treatment exposure when compared to second line
TROPiCS-02 trial results reinforce the role of sacituzumab govitecan (SG) for chemo-refractory patients with HR+/HER2- metastatic breast cancer. The study reports a significant OS improvement when using SG compared to chemotherapy, irrespective of HER2-low status or Trop2 expression
Coming soon: New Oral Endocrine Therapy Options in Breast Cancer - an interactive online event hosted by breast cancer experts. Register here.